Flt3/MerTK Inhibitor MRX-2843 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MRX 2843, MRX-2843, MRX2843

Filter by location:

Atlanta, Georgia1 trial

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory University Hospital/Winship Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.